Cargando…

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a complex condition that displays heterogeneity in disease severity and response to standard treatments between patients. Failure rates for conventional, target synthetic, and biologic disease-modifying rheumatic drugs (DMARDs) are significant. Although there are models...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Susan Siyu, Lewis, Myles J., Pitzalis, Costantino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377185/ https://www.ncbi.nlm.nih.gov/pubmed/37509625 http://dx.doi.org/10.3390/biomedicines11071987

Ejemplares similares

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients
por: Sun, Zhijian, et al.
Publicado: (2022)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
por: Gomez, Esteban A., et al.
Publicado: (2020)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Comparison of Hand-Wrist Findings of Rheumatoid Arthritis Patients According to the Use of Synthetic and Biological Disease-Modifying Antirheumatic Drugs (DMARDs): A Clinical, Radiographic, and Ultrasonographic Study
por: Cinar, Cigdem, et al.
Publicado: (2023)

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
por: Jung, Gyu-Un, et al.
Publicado: (2018)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Costello, Ruth E, et al.
Publicado: (2020)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
por: Ozen, Gulsen, et al.
Publicado: (2019)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Frequency and trends of disease‐modifying antirheumatic drug (DMARD) use in Germany
por: Fassmer, Alexander M., et al.
Publicado: (2016)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
por: Deng, Daihua, et al.
Publicado: (2020)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs
por: Rivellese, Felice, et al.
Publicado: (2020)

Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
por: Baker, Matthew C., et al.
Publicado: (2023)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
por: Sato, Shuzo, et al.
Publicado: (2021)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment
por: Miwa, Yusuke, et al.
Publicado: (2017)

The Cost-Effectiveness of and Adherence to Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis Patients in a Tertiary Care Teaching Hospital in Uttarakhand, India
por: Mittal, Gauri, et al.
Publicado: (2023)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry
por: Mease, Philip J., et al.
Publicado: (2021)

Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis
por: Beckers, Esther, et al.
Publicado: (2023)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2016)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h439lopptb1p48nj0h8oq5cicu